Evidence map›Paper›PMID 39901510›Full record

ArticleEpidemiology and infection2025

SARS-CoV-2 vaccination influence in the development of long-COVID clinical phenotypes.

Patrizia Pasculli, Michele Antonacci, Maria Antonella Zingaropoli, Federica Dominelli, Federica Ciccone, Francesco Pandolfi, Yann Collins Fosso Ngangue, Giorgio Maria Masci, Roberta Campagna, Franco Iafrate and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Patrizia PasculliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Michele AntonacciDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.ORCID 0009-0001-9673-5487
Maria Antonella ZingaropoliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Federica DominelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Federica CicconeDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Francesco PandolfiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Yann Collins Fosso NgangueDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Giorgio Maria MasciDepartment of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Roberta CampagnaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Franco IafrateDepartment of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Valeria PanebiancoDepartment of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Carlo CatalanoDepartment of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Ombretta TurrizianiDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Gioacchino GalardoMedical Emergency Unit, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy.
Paolo PalangeDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Claudio Maria MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Maria Rosa CiardiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although SARS-CoV-2 vaccination reduces hospitalization and mortality, its long-term impact on Long-COVID remains to be elucidated. The aim of the study was to evaluate the different development of Long-COVID clinical phenotypes according to the vaccination status of patients. Clinical and demographic characteristics were assessed for each patient, while Long-COVID symptoms were self-reported and later stratified into distinct clinical phenotypes. Vaccination was significantly associated with the avoidance of hospitalization, less invasive respiratory support, and less alterations of cardiopulmonary functions, as well as reduced lasting lung parenchymal damage. However, no association between vaccination status and the development of at least one Long-COVID symptom was found. Nevertheless, clinical phenotypes were differently associated with vaccination status, as neuropsychiatric were more frequent in unvaccinated patients and cardiorespiratory symptoms were reported mostly in vaccinated patients. Different progression of disease could be at play in the different development of specific Long-COVID clinical phenotypes, as shown by the different serological responses between unvaccinated and vaccinated patients. A higher anti-Spike (

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2VaccinationAdultAgedAntibodies, ViralFemaleHospitalizationHumansMaleMiddle AgedPhenotypeAntibodies, ViralCOVID-19 Vaccinesanti-S antibodiesCOVID-19mRNA vaccinePASCpost-COVID-19 syndrome

Identifiers

PMID39901510
PMCPMC11869074

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.